Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

APP Pharmaceuticals, The Medicines Co. settle Angiomax patent litigation

Executive Summary

Fresenius Kabi AG’s APP Pharmaceuticals Inc. has settled patent litigation with The Medicines Co. pertaining to APP’s ANDA for a generic form of TMC’s Angiomax (bivalirudin injection) to prevent blood clots. TMC has granted APP a license to begin marketing an Angiomax generic in the US on May 1, 2019--or sooner under certain circumstances--and the agreement may include the right to sell an authorized bivalirudin generic supplied by TMC. (The TMC patents that were in question are set to expire at the end of July 2028.) APP also agreed to manufacture and supply TMC with a finished Angiomax product. APP will license and supply TMC with a portfolio of ten generics for acute cardiovascular, neurological, and infectious diseases in the hospital setting; for this license TMC will pay $30mm up front.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Manufacturing or Supply
    • R+D and Marketing-Licensing

Related Companies